share_log

AbbVie | 10-Q: Q2 2024 Earnings Report

AbbVie | 10-Q: Q2 2024 Earnings Report

艾伯維公司 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/08 03:01

Moomoo AI 已提取核心訊息

AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
AbbVie reported Q2 2024 global net revenues of $14.5 billion, increasing 4.3% year-over-year, with operating earnings of $4.0 billion and diluted EPS of $0.77. The growth was primarily driven by Skyrizi and Rinvoq, which saw revenues surge 44.8% and 55.8% respectively, helping offset a 29.8% decline in Humira sales due to biosimilar competition.The company completed its acquisition of ImmunoGen for $9.8 billion in February 2024, strengthening its oncology portfolio with Elahere which contributed $128 million in Q2 revenues. AbbVie issued $15 billion in senior notes to finance the ImmunoGen and Cerevel Therapeutics acquisitions. The gross margin improved to 71% from 69% in Q2 2023, benefiting from lower amortization of intangibles.Research and development expenses increased 12% to $1.9 billion as AbbVie continued investing in its pipeline. The company maintained its quarterly dividend at $1.55 per share and repurchased 5 million shares for $959 million during H1 2024. The effective tax rate was 36% for Q2 2024, up from 22% in Q2 2023, primarily due to business development activities.
艾伯維公司報告2024年第二季度全球淨收入爲145億美金，同比增長4.3%，營業收入爲40億美金，攤薄後每股收益爲0.77美金。增長主要得益於Skyrizi和Rinvoq，二者的收入分別激增44.8%和55.8%，幫助抵消了因生物相似藥競爭而導致的Humira銷售下降29.8%。該公司於2024年2月完成了對ImmunoGen的98億美金收購，增強了其腫瘤學產品組合，其中Elahere在第二季度產生了12800萬美金的收入。艾伯維公司發行了150億美金的高級票據，以融資ImmunoGen和Cerevel Therapeutics的收購。毛利率從2023年第二季度的69%提升至71%，受益於無形...展開全部
艾伯維公司報告2024年第二季度全球淨收入爲145億美金，同比增長4.3%，營業收入爲40億美金，攤薄後每股收益爲0.77美金。增長主要得益於Skyrizi和Rinvoq，二者的收入分別激增44.8%和55.8%，幫助抵消了因生物相似藥競爭而導致的Humira銷售下降29.8%。該公司於2024年2月完成了對ImmunoGen的98億美金收購，增強了其腫瘤學產品組合，其中Elahere在第二季度產生了12800萬美金的收入。艾伯維公司發行了150億美金的高級票據，以融資ImmunoGen和Cerevel Therapeutics的收購。毛利率從2023年第二季度的69%提升至71%，受益於無形資產的攤銷減少。研發費用增加12%，達到19億美金，因爲艾伯維公司繼續投資其研發管道。該公司將季度股息維持在每股1.55美金，並在2024年上半年回購了500萬股，耗資95900萬美金。2024年第二季度的有效稅率爲36%，較2023年第二季度的22%有所上升，主要是由於業務開發活動。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    施貴寶
    BMY
    -- 60.020
    默沙東
    MRK
    -- 89.230
    賽諾菲安萬特
    SNY
    -- 55.820
    阿斯利康
    AZN
    -- 73.790
    艾伯維公司
    ABBV
    -- 205.290
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日